|Bid||2.4300 x 800|
|Ask||2.5200 x 900|
|Day's Range||2.3300 - 2.4650|
|52 Week Range||1.7400 - 4.4000|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
Chimerix (CMRX) delivered earnings and revenue surprises of -105.88% and -37.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Pipeline Transformed with Acquisition of Global Rights to Late Stage Oncology Asset (CX-01) with Fast Track and Orphan Drug Designation Phase 3 Trial of CX-01 in Front-Line.
Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chimerix tapped former Endocyte executive Michael Sherman as CEO in April following the sudden departure of former CEO Michelle Berry. The company has raised $34.9 million from just one investor, according to a filing with the Securities and Exchange Commission. That funding was all but gone as soon as it came in however, with Chimerix (Nasdaq: CMRX) announcing a licensing deal with Florida-based Cantex Pharmaceuticals for the exclusive rights to its CX-01 – a potential treatment for Acute Myeloid Leukemia. The deal has Chimerix paying $30 million upfront, with up to $587 million in milestone payments and tiered royalties beginning at 10 percent. The deal also awards Cantex 10 million shares of Chimerix’s common stock. In a call with analysts following the announcement, Sherman said the company's interest in the drug fell perfectly in line with its decision to bring on a license with "proof of concept data in hand" and one with the potential to have "significant impact" on a patient population.
Chimerix (CMRX), today announced the completion of an exclusive worldwide license of CX-01 from Cantex Pharmaceuticals, Inc. Chimerix intends to move quickly into Phase 3 development of CX-01 for the treatment of Acute Myeloid Leukemia (AML) in the first-line setting. “We are pleased to have made such rapid progress in repositioning the company and transforming our pipeline with this important cancer therapy.
Does Chimerix Inc (NASDAQ:CMRX) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]
Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and 17.80%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Durham, North Carolina-based company said it had a loss of 35 cents per share. The biopharmaceutical company posted revenue of $2.4 million in the period. The company's shares closed at $2.68. A year ...
– Reports Positive Top-line Survival Data from Pivotal Mouse Study as Key Milestone on Path to Smallpox Regulatory Submission – – Plan to Focus on Execution of Smallpox.
NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time. ...
DURHAM, N.C., May 02, 2019 -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today.
Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you own shares in Chimerix, Inc. (NASDAQ:CMRX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volatili...
Following the sudden departure of its last CEO earlier this year, Chimerix has tapped a pair of Endocyte executives to lead the company.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 8) Alector Inc (NASDAQ: ALEC ) Denali Therapeutics Inc ...
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announces the appointment of Michael A. Sherman, former Chief Executive Officer of Endocyte, Inc., as Chief Executive Officer of Chimerix, effective immediately.
One of Chimerix's development and commercial partners is out, disclosing this week it would be terminating a four-year-old licensing agreement after deciding to drop Chimerix's drug – the second time in less than five years the drug has been abandoned.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
– Reports Positive Preliminary Top-line Data from Second Rabbitpox Study – – Type C Meeting Requested with FDA Regarding Virologic Endpoint – – Conference Call at 8:30.